RY is a member of the Stanley Medical Research Institute Board of Directors and Scientific Advisory Board. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies. FD, CS, AO, CV, SK, and AA have no biomedical financial interests or potential conflicts of interest to report.
Markers of gluten sensitivity and celiac disease in bipolar disorder
Article first published online: 14 FEB 2011
© 2011 John Wiley and Sons A/S
Volume 13, Issue 1, pages 52–58, February 2011
How to Cite
Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Khushalani, S., Alaedini, A. and Yolken, R. (2011), Markers of gluten sensitivity and celiac disease in bipolar disorder. Bipolar Disorders, 13: 52–58. doi: 10.1111/j.1399-5618.2011.00894.x
- Issue published online: 14 FEB 2011
- Article first published online: 14 FEB 2011
- Received 9 June 2010, revised and accepted for publication 28 December 2010
- bipolar disorder;
- celiac disease;
- gliadin antibody;
- gluten sensitivity
Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Alaedini A, Yolken R. Markers of gluten sensitivity and celiac disease in bipolar disorder. Bipolar Disord 2011: 13: 52–58. © 2011 The Authors. Journal compilation © 2011 John Wiley & Sons A/S.
Objectives: Increased immune sensitivity to dietary gluten proteins has been reported in schizophrenia but has not been studied in bipolar disorder. In this study, we examine the levels of antibody reactivity to gliadin, deamidated gliadin, and tissue transglutaminase (tTG) in individuals with bipolar disorder and compare these levels to those in individuals who do not have any history of psychiatric disorder.
Methods: The sample of 275 individuals included 102 with bipolar disorder and 173 controls without a psychiatric disorder. Immunoglobulin G (IgG) and immunoglobulin A (IgA) antibodies to gliadin and tTG and IgG antibodies to deamidated gliadin were measured by enzyme immunoassay. Participants’ levels of antibodies to deamidated gliadin and tTG were classified based on the cutoffs for positivity that are predictive of celiac disease. Quantitative levels of antibodies were compared between groups employing regression models which were controlled for demographic variables.
Results: Individuals with bipolar disorder had increased levels of IgG antibodies to gliadin compared with controls in multivariate analyses. We also found evidence of increased levels of antibodies to deamidated gliadin in the bipolar disorder population. The levels of IgA class antigliadin antibodies and antibodies to tTG did not differ significantly between groups. There was also not a significant difference between groups in the number of persons who were classified as having levels of antibodies to deamidated gliadin or tTG that are predictive of celiac disease.
Conclusions: Individuals with bipolar disorder have increased levels of IgG antibodies to gliadin. However, such antibody increase is not accompanied by an elevation in IgA antibodies to gliadin or the celiac disease-associated antibodies against deamidated gliadin and tTG. These results warrant further detailed examination of the molecular specificity and pattern of reactivity of the antibody response to gluten antigens in bipolar disorder.